Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma.
暂无分享,去创建一个
Albrecht Reichle | Michael Landthaler | Ulrich Hohenleutner | Christian Hafner | M. Landthaler | T. Vogt | C. Hafner | U. Hohenleutner | R. Szeimies | A. Reichle | Thomas Vogt | Rolf-Markus Szeimies | Brigitte Coras | B. Coras
[1] Susan M. Kilroy,et al. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. , 2002, The Journal of clinical investigation.
[2] Peter Bohlen,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .
[3] S. Gately. The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.
[4] Kaposi,et al. Idiopathisches multiples Pigmentsarkom der Haut , 1872, Archiv für Dermatologie und Syphilis.
[5] M. Landthaler,et al. Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma. , 1998, British Journal of Cancer.
[6] Y. Chang,et al. Kaposi's sarcoma. , 2000, The New England journal of medicine.
[7] M. Landthaler,et al. Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors , 2003, Cancer.
[8] G. Hempel,et al. Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer. , 1997, Anti-cancer drugs.
[9] D. S. Santa Cruz,et al. Kaposi's sarcoma , 1992, Journal of cutaneous pathology.
[10] D. Aboulafia,et al. Kaposi's sarcoma. , 2001, Clinics in dermatology.
[11] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[12] J. Masferrer. Approach to angiogenesis inhibition based on cyclooxygenase-2. , 2001, Cancer journal.
[13] W. Stolz,et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II , 2001, Melanoma research.
[14] P. Monini,et al. Treatment of Kaposi's sarcoma—an update , 2002, Anti-cancer drugs.
[15] K. Kinzler,et al. PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.
[16] Samuel Singer,et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.